ImmunoSIGNAL Cytokine Storm Cellular Assay is an in vitro assay that evaluates biologics for their potential to induce cytokine release syndrome, a potentially fatal immune reaction that has been associated with monoclonal antibody therapy. In this assay, compounds are evaluated for their ability to stimulate human peripheral blood mononuclear cells to secrete specific cytokines and chemokines. The assay uses air-dry antibody binding, which produces superior induction of T cell cytokines, inflammatory cytokines, and chemokines.
Dr. Usha Warrior, Ricerca technical director of in vitro pharmacology, said, “Bringing these crucial screening assays to the earliest stages of drug discovery with this cost-effective model liberates our clients from having to invest capital and time. Ricerca has the capacity to screen hundreds of compounds a week with these new assays.”